相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy
Feihu Wang et al.
SCIENCE ADVANCES (2020)
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Qian Chen et al.
NATURE NANOTECHNOLOGY (2019)
Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy
Daniel Shae et al.
NATURE NANOTECHNOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy.
David G. Leach et al.
BIOMATERIALS (2018)
Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
David R. Wilson et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
Chun Gwon Park et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
Chao Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Recombinant Listeria promotes tumor rejection by CD8+ T cell-dependent remodeling of the tumor microenvironment
Weiwen Deng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response
Assaf Marcus et al.
IMMUNITY (2018)
Rationale for stimulator of interferon genes-targeted cancer immunotherapy
Thaiz Rivera Vargas et al.
EUROPEAN JOURNAL OF CANCER (2017)
Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model
Shekhar K. Gadkaree et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy
Sandeep T. Koshy et al.
ADVANCED BIOSYSTEMS (2017)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer et al.
CELL (2017)
STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation
Ken Takashima et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Haidong Tang et al.
CANCER CELL (2016)
Chemotherapy and immunotherapy: mapping the road ahead
Alistair M. Cook et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Make better, safer biomaterials
Nicholas A. Peppas et al.
NATURE (2016)
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Dimitrios Mathios et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
Ellen Moore et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment A Prospective Study
Giuseppe Lombardi et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
Olivier Demaria et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
STING: infection, inflammation and cancer
Glen N. Barber
NATURE REVIEWS IMMUNOLOGY (2015)
Linker-determined drug release mechanism of free camptothecin from self-assembling drug amphiphiles
Andrew G. Cheetham et al.
CHEMICAL COMMUNICATIONS (2014)
Intrinsic Self-DNA Triggers Inflammatory Disease Dependent on STING
Jeonghyun Ahn et al.
JOURNAL OF IMMUNOLOGY (2014)
Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy
Christel Devaud et al.
MOLECULAR THERAPY (2014)
STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Dinesh Chandra et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING
Andrea Ablasser et al.
NATURE (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
Jiaxi Wu et al.
SCIENCE (2013)
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Lijun Sun et al.
SCIENCE (2013)
Murine leukemia virus envelope gp70 is a shared biomarker for the high-sensitivity quantification of murine tumor burden
Francesca Scrimieri et al.
ONCOIMMUNOLOGY (2013)
Antitumor immune responses mediated by dendritic cells How signals derived from dying cancer cells drive antigen cross-presentation
Lotte Spel et al.
ONCOIMMUNOLOGY (2013)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Mercedes B. Fuertes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Mark S. Diamond et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
Kazuki N. Sugahara et al.
CANCER CELL (2009)
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Hiroki Ishikawa et al.
NATURE (2009)
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Hiroki Ishikawa et al.
NATURE (2008)
分享论文
